Appointment of Non-Executive Director, Redx Pharma plc, 2020-05-18

RNS Number : 1190N
Redx Pharma plc
18 May 2020


(“Redx” or “the Company”)


Appointment of Non-Executive Director with Deep Experience of the Biotechnology Industry and Capital Markets


Alderley Park, 18 May 2020 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce the appointment of Sarah Gordon Wild as an Independent non-Executive Director, with effect from 1 July 2020. Sarah brings extensive investment experience in the biotechnology sector to her role at Redx. She currently also serves as a Non-Executive Director of Oxford Nanopore Technologies and Evox Therapeutics, as well as being a Board Member of Lone Pine Capital LLC’s Offshore Funds.


Between 1998-2003 Sarah was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC. Before this, for over 15 years, Sarah was a senior biotechnology/healthcare analyst on Wall Street at firms including; Amerindo Investments Advisors, Hambrecht & Quist, Kleinwort Grieveson, and Greig Middleton. She graduated from Aberdeen University with a BSc (Hons) in Zoology and with an MSc from Imperial College, London in Social & Economic Aspects of Science and Technology in Industry.


Iain Ross, Chairman of the Board of Redx commented: “We are delighted to welcome Sarah to the Board. I am confident that Redx will benefit from her counsel and deep understanding of the biotechnology sector and capital markets as we seek to build a leading biotech company focused on novel medicines that have the potential to transform the treatment of oncology and fibrosis.”


Sarah Gordon Wild commented: “I am excited to be joining the Board as a non-executive director. Over a relatively short space of time, Redx has established a strong track record as a medicinal chemistry team and now has focused on a few very exciting programmes, as well as a strong management team.  I look forward to seeing this pipeline progress in my Board role.” 


Additional information:


The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:


Sarah Gordon Wild, aged 61, is currently a director of:


·    Oxford Nanopore Technologies Limited

·    Evox Therapeutics Limited

·    SGW Research Limited

·    Larkham Limited

·    The Bridport Literary Festival Limited

·    Leweston School Trust


She is a partner in Dukes Auctioneers (Dorchester)


She is also a member of the Lone Pine Capital Offshore Board


She does not currently hold any ordinary shares in the Company.


For further information, please contact:


Redx Pharma Plc 

T: +44 1625 469 918

Iain Ross, Chairman

Lisa Anson, Chief Executive

Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

 T: +44 20 7894 7000

Phil Davies

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin


About Redx Pharma Plc


Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.


If you would like to sign up to regular alerts from Redx Pharma, please follow this link



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit




Leave a Reply

Your email address will not be published.